June 14, 2025
4 min watch
CHICAGO — On this video, Erica L. Mayer, MD, MPH, director of breast most cancers medical analysis at Dana-Farber Most cancers Institute, discusses outcomes of the TRADE examine, which she offered at ASCO Annual Assembly.
The section 2 trial assessed tolerability of abemaciclib (Verzenio, Eli Lilly & Co.) dose escalation amongst sufferers with early-stage hormone receptor-positive, HER2-negative stage II and III breast most cancers. Outcomes confirmed 70% of sufferers achieved and maintained the goal dose of 150 mg twice every day by 12 weeks.
“We hope this can be a profitable technique that suppliers can use in clinic that may permit sufferers to get the utmost profit out of abemaciclib,” Mayer mentioned.
Sources/Disclosures
Collapse
Mayer EL, et al. The TRADE examine: A section 2 trial to evaluate the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast most cancers. Offered at: ASCO Annual Assembly; Could 30-June 3, 2025; Chicago.
Disclosures:
Eli Lilly & Co. supported this examine. Mayer stories consulting for AstraZeneca, Eli Lilly & Co. and Novartis.
